Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

PROLOR Biotech Awarded Two U.S. Patents For Its Longer-Acting Human Growth Hormone And Longer-Acting Erythropoietin
PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH), formerly Modigene Inc., announced that the U. S. Patent and Trademark Office (PTO) has issued two new patents for the company"s long-acting CTP-enhanced human growth hormone (hGH-CTP) and human erythropoietin (EPO-CTP). The patents cover the composition of PROLOR"s proprietary pharmaceutical compounds as well as certain associated methods. PROLOR"s CTP technology is based on a short amino acid sequence, the Carboxyl Terminal Peptide that occurs naturally in humans. When attached to a therapeutic protein, CTP extends the time that the protein is active in the body.

Managing Erosion Caused By Everyday Beverages
Researchers have warned people to beware of the damage that acidic beverages have on teeth. Yet, for some, the damage and problems associated with drinking sodas, citric juices or certain tea may have already begun to take effect. The question remains: What can be done to restore teeth already affected?
News of the day
Faith Group Leaders Come Together To Support 'Wall Of Life'
Leaders of the major faith groups have put their support behind the Wall of Life, an interactive campaign launched today by NHS Blood and Transplant (NHSBT). The campaign - at http://www.walloflife.org.uk - aims to promote awareness of and support for organ donation to boost the number of people joining the NHS Organ Donor Register (ODR).
Nutrition

UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®. "Our PEGylation technology continues to enable very important therapeutics like Cimzia, benefiting patients with a wide variety of diseases," said Jeffrey H. Buchalter, Enzon"s chairman and chief executive officer. About CIMZIA® Cimzia® is the only PEGylated anti-TNF (Tumor Necrosis Factor). Cimzia® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation. This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases. The U.S. Food and Drug Administration (FDA) has approved Cimzia® for reducing signs and symptoms of Crohn"s disease and maintaining clinical response in adult patients with moderate to severe active disease who have had an inadequate response to conventional therapy and for the treatment of adults with moderate to severely active rheumatoid arthritis. Cimzia® was approved in Switzerland for induction of a clinical response and for the maintenance of a clinical response and remission in patients with active Crohn"s disease who have not responded adequately to conventional treatment in September 2007. UCB is also developing Cimzia® in other autoimmune disease indications. Cimzia® is a registered trademark of UCB PHARMA S.A. Enzon Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009